897
Views
18
CrossRef citations to date
0
Altmetric
Commentary

Particle based vaccine formulations for transcutaneous immunization

, , &
Pages 1950-1955 | Received 15 May 2013, Accepted 30 May 2013, Published online: 18 Jun 2013

References

  • Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992; 1104:226 - 32; http://dx.doi.org/10.1016/0005-2736(92)90154-E; PMID: 1550849
  • Gratieri T, Schaefer UF, Jing L, Gao M, Kostka KH, Lopez RF, et al. Penetration of quantum dot particles through human skin. J Biomed Nanotechnol 2010; 6:586 - 95; http://dx.doi.org/10.1166/jbn.2010.1155; PMID: 21329051
  • Gupta PN, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 2005; 293:73 - 82; http://dx.doi.org/10.1016/j.ijpharm.2004.12.022; PMID: 15778046
  • Paul A, Cevc G, Bachhawat BK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 1998; 16:188 - 95; http://dx.doi.org/10.1016/S0264-410X(97)00185-0; PMID: 9607029
  • Geusens B, Van Gele M, Braat S, De Smedt SC, Stuart MCA, Prow TW, et al. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv Funct Mater 2010; 20:4077 - 90; http://dx.doi.org/10.1002/adfm.201000484
  • Mishra D, Mishra PK, Dubey V, Nahar M, Dabadghao S, Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 2008; 33:424 - 33; http://dx.doi.org/10.1016/j.ejps.2008.01.015; PMID: 18359615
  • Wang J, Hu JH, Li FQ, Liu GZ, Zhu QG, Liu JY, et al. Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp Dermatol 2007; 16:724 - 9; http://dx.doi.org/10.1111/j.1600-0625.2007.00584.x; PMID: 17697144
  • Hansen S, Lehr C-M. Nanoparticles for transcutaneous vaccination. Microb Biotechnol 2012; 5:156 - 67; http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x; PMID: 21854553
  • Romero EL, Morilla MJ. Topical and mucosal liposomes for vaccine delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 3:356 - 75; http://dx.doi.org/10.1002/wnan.131; PMID: 21360692
  • Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci 2006; 91:159 - 65; http://dx.doi.org/10.1093/toxsci/kfj122; PMID: 16443688
  • Patzelt A, Richter H, Knorr F, Schäfer U, Lehr CM, Dähne L, et al. Selective follicular targeting by modification of the particle sizes. J Control Release 2011; 150:45 - 8; http://dx.doi.org/10.1016/j.jconrel.2010.11.015; PMID: 21087645
  • Mittal A, Raber AS, Schaefer UF, Weissmann S, Ebensen T, Schulze K, et al. Non-invasive delivery of nanoparticles to hair follicles: A perspective for transcutaneous immunization. Vaccine 2013; In Press http://dx.doi.org/10.1016/j.vaccine.2012.12.048; PMID: 23290836
  • Jacobi U, Engel K, Patzelt A, Worm M, Sterry W, Lademann J. Penetration of pollen proteins into the skin. Skin Pharmacol Physiol 2007; 20:297 - 304; http://dx.doi.org/10.1159/000108101; PMID: 17851273
  • Fan H, Lin Q, Morrissey GR, Khavari PA. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999; 17:870 - 2; http://dx.doi.org/10.1038/12856; PMID: 10471927
  • Shaker DS, Sloat BR, Le UM, Löhr CV, Yanasarn N, Fischer KA, et al. Immunization by application of DNA vaccine onto a skin area wherein the hair follicles have been induced into anagen-onset stage. Mol Ther 2007; 15:2037 - 43; http://dx.doi.org/10.1038/sj.mt.6300286; PMID: 17700542
  • Baleeiro RB, Wiesmüller KH, Reiter Y, Baude B, Dähne L, Patzelt A, et al. Topical Vaccination with Functionalized Particles Targeting Dendritic Cells. J Invest Dermatol 2013; In Press http://dx.doi.org/10.1038/jid.2013.79; PMID: 23426134
  • Combadière B, Vogt A, Mahé B, Costagliola D, Hadam S, Bonduelle O, et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 2010; 5:e10818; http://dx.doi.org/10.1371/journal.pone.0010818; PMID: 20520820
  • Otberg N, Patzelt A, Rasulev U, Hagemeister T, Linscheid M, Sinkgraven R, et al. The role of hair follicles in the percutaneous absorption of caffeine. Br J Clin Pharmacol 2008; 65:488 - 92; http://dx.doi.org/10.1111/j.1365-2125.2007.03065.x; PMID: 18070215
  • Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, et al. Nanoparticles--an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 2007; 66:159 - 64; http://dx.doi.org/10.1016/j.ejpb.2006.10.019; PMID: 17169540
  • Mitragotri S. Mechanical disruption of skin barrier for vaccine delivery. Drug Deliv Syst 2012; 27:202 - 12; http://dx.doi.org/10.2745/dds.27.202
  • Lopez RF, Seto JE, Blankschtein D, Langer R. Enhancing the transdermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate. Biomaterials 2011; 32:933 - 41; http://dx.doi.org/10.1016/j.biomaterials.2010.09.060; PMID: 20971504
  • Karande P, Mitragotri S. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu Rev Chem Biomol Eng 2010; 1:175 - 201; http://dx.doi.org/10.1146/annurev-chembioeng-073009-100948; PMID: 22432578
  • Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy. [2] N Engl J Med 1999; 340:1683 - 4; http://dx.doi.org/10.1056/NEJM199905273402114; PMID: 10348681
  • Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, et al. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine 2011; 29:5558 - 66; http://dx.doi.org/10.1016/j.vaccine.2011.01.064; PMID: 21300092
  • Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Újhelyi E, et al. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One 2012; 7:e35416; http://dx.doi.org/10.1371/journal.pone.0035416; PMID: 22590502
  • Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, Snowball M, et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000; 18:1939 - 43; http://dx.doi.org/10.1016/S0264-410X(99)00446-6; PMID: 10699344
  • Matheï C, Van Damme P, Meheus A. Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle. Vaccine 1997; 15:402 - 4; http://dx.doi.org/10.1016/S0264-410X(96)00196-X; PMID: 9141211
  • Millar JD, Morris L, Macedo Filho A, Mack TM, Dyal W, Medeiros AA. The introduction of jet injection mass vaccination into the national smallpox eradication program of Brazil. Trop Geogr Med 1971; 23:89 - 101; PMID: 5573585
  • Abb J, Deinhardt F, Eisenburg J. The risk of transmission of hepatitis B virus using jet injection in inoculation. J Infect Dis 1981; 144:179; http://dx.doi.org/10.1093/infdis/144.2.179; PMID: 7276631
  • Demuth PC, Garcia-Beltran WF, Ai-Ling ML, Hammond PT, Irvine DJ. Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination. Adv Funct Mater 2013; 23:161 - 72; http://dx.doi.org/10.1002/adfm.201201512; PMID: 23503923
  • Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007; 6:797 - 808; http://dx.doi.org/10.1586/14760584.6.5.797; PMID: 17931159
  • Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2007; 4:73 - 84; http://dx.doi.org/10.1021/mp060096p; PMID: 17274665
  • Rancan F, Gao Q, Graf C, Troppens S, Hadam S, Hackbarth S, et al. Skin penetration and cellular uptake of amorphous silica nanoparticles with variable size, surface functionalization, and colloidal stability. ACS Nano 2012; 6:6829 - 42; http://dx.doi.org/10.1021/nn301622h; PMID: 22797484
  • Ma YF, Zhuang Y, Xie XF, Wang C, Wang F, Zhou DM, et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 2011; 3:2307 - 14; http://dx.doi.org/10.1039/c1nr10166h; PMID: 21499635
  • Higa LH, Schilrreff P, Perez AP, Iriarte MA, Roncaglia DI, Morilla MJ, et al. Ultradeformable archaeosomes as new topical adjuvants. Nanomedicine 2012; 8:1319 - 28; http://dx.doi.org/10.1016/j.nano.2012.02.008; PMID: 22366598
  • Uto T, Akagi T, Hamasaki T, Akashi M, Baba M. Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunol Lett 2009; 125:46 - 52; http://dx.doi.org/10.1016/j.imlet.2009.05.008; PMID: 19505507
  • Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371:2019 - 25; http://dx.doi.org/10.1016/S0140-6736(08)60839-9; PMID: 18554712
  • Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants--a balance between toxicity and adjuvanticity. Vaccine 1993; 11:293 - 306; http://dx.doi.org/10.1016/0264-410X(93)90190-9; PMID: 8447157
  • Diwan M, Elamanchili P, Cao M, Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv 2004; 1:405 - 12; http://dx.doi.org/10.2174/1567201043334597; PMID: 16305402
  • Wilson KD, de Jong SD, Tam YK. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev 2009; 61:233 - 42; http://dx.doi.org/10.1016/j.addr.2008.12.014; PMID: 19232375
  • Bershteyn A, Hanson MC, Crespo MP, Moon JJ, Li AV, Suh H, et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J Control Release 2012; 157:354 - 65; http://dx.doi.org/10.1016/j.jconrel.2011.07.029; PMID: 21820024
  • Fischer S, Schlosser E, Mueller M, Csaba N, Merkle HP, Groettrup M, et al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 2009; 17:652 - 61; http://dx.doi.org/10.1080/10611860903119656; PMID: 19622019
  • Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008; 26:1626 - 37; http://dx.doi.org/10.1016/j.vaccine.2008.01.030; PMID: 18295941
  • Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 2011; 29:1045 - 52; http://dx.doi.org/10.1016/j.vaccine.2010.11.061; PMID: 21129393

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.